Efficacy and safety of rivaroxaban in elderly patients with nonvalvular atrial  fibrillation complicated with cardiac insufficiency

doi:10.3969/j.issn.1004-583X.2020.05.005

Abstract

Abstract: Objective To analyze the clinical efficacy and safety of rivaroxabanin elderly patients with nonvalvular atrial fibrillation (NVAF) complicated with cardiac insufficiency. Methods A total of 182 elderly NVAF patients complicated with cardiac insufficiency who were admitted to the hospital from January 2016 to January 2020 were enrolled. The patients were randomly divided into two groups, 91 cases were selected for rivaroxaban anticoagulation as observation group, and other 91 cases were treated with warfarin anticoagulation as control group. The adverse events including thrombotic events, hemorrhage, and coagulation, as well as the coagulation function and cardiac function were recorded during the followup in two groups. Results The total bleeding events in observation group were significantly lower than those in control group. NTproBNP of observation group significantly decreased compared with that of control group after treatment. COX risk model found that the age and warfarin were risk factors for adverse events. Conclusion Rivaroxaban is not inferior to warfarin in treating the elderly NVAF patients complicated with cardiac insufficiency, but its safety is significantly higher than that of warfarin.

Key words: atrial fibrillation, nonvalvular; , rivaroxaban, cardiac insufficiency; , the elderly; , efficacy, safety

Ma Jincai, Ma Rongzhi, Ma Zhenzhen. Efficacy and safety of rivaroxaban in elderly patients with nonvalvular atrial fibrillation complicated with cardiac insufficiency[J]. Clinical Focus, doi: 10.3969/j.issn.1004-583X.2020.05.005.

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2020.05.005

https://huicui.hebmu.edu.cn/EN/Y2020/V35/I5/413

[1]	Wang Yihan, Qin Xuyan, Han Xuanze, Wang Yingjie, Gao Feifei, Chen Chunhong, Zhang Lingnan, Zhang Fang. Efficacy and safety of rivaroxaban therapy in elderly patients with non-valvular atrial fibrillation who had a HASBLED score≥3 [J]. Clinical Focus, 2024, 39(2): 121-124.
[2]	Li Hai, Liu Wenhu, Peng Shaopeng, Wang Fei. Meta-analysis of the efficacy of controlled stepwise decompression versus rapid standard large bone-flap decompression on the treatment of severe craniocerebral injury [J]. Clinical Focus, 2023, 38(9): 788-795.
[3]	Wang Zhen, Yang Xiaoyue, Li Shaojie, Wang Xian, Chen Shuxia, Gu Jian. Analysis of clinical characteristics and readmission risk factors in patients with ejection fraction preserved heart failure combined with atrial fibrillation [J]. Clinical Focus, 2023, 38(4): 308-314.
[4]	Zhang Fang, Zhang Yichao, Jia Xinwei, Li Jianlong, Chen Chunhong. Analysis of one-year follow-up results of ≥75-year-old atrial fibrillation inpatients with high CHA2DS2-VASc score [J]. Clinical Focus, 2023, 38(2): 117-120.
[5]	Ma Jinghong, Yang Qian, Jia Yongjian, Dang Yi. Risks of cardiac tamponade resulting from uninterrupted novel oral anticoagulants and uninterrupted warfarin during perioperative period of catheter ablation of atrial fibrillation: A meta-analysis [J]. Clinical Focus, 2022, 37(9): 773-778.
[6]	Wang Tengyan, He Yajun, Shu Jianchang. Rebamipide in the treatment of nonsteroidal anti-inflammatory drug-associated intestinal disease: A meta-analysis [J]. Clinical Focus, 2022, 37(8): 685-690.
[7]	Zhang Jingshui, Xu Yanan, Wang Jun, Yang Yi, Jiang Haibing, Tang Long, Wang Xianping, Shao Mingliang. Clinical characteristics and long-term prognosis of initial patients with new onset different type of heart failure combined atrial fibrillation [J]. Clinical Focus, 2022, 37(6): 504-509.
[8]	Zhang Haifu, Ye Xiangqing, Chen Zhexu, Chen Shijian, Yang Dong, Zhang Xingwei. Effects of moderate exercise on the prognosis of patients with atrial fibrillation:A systematic review and Meta-analysis [J]. Clinical Focus, 2022, 37(6): 485-489.
[9]	Li Shufan, Wang Yuxiu, Jiang Zhenghua. The correlation between the prognosis of lung adenocarcinoma with acquired resistance to the first-generation EGFR TKI and the T790M mutation [J]. Clinical Focus, 2022, 37(11): 985-991.
[10]	Li Weiwei, Li Yanan. Left atrial volume index predicts atrial fibrillation recurrence after radiofrequency ablation: A meta-analysis [J]. Clinical Focus, 2022, 37(11): 965-968.
[11]	An Jingjing, Wang Xiaojuan, Deng Aiyun. Radiofrequency ablation in treating pre-excited atrial fibrillation recurrence: A meta analysis [J]. Clinical Focus, 2022, 37(10): 899-904.
[12]	Zhao Meili, Xiao Liyuan, Liu Lin, Kang Chao, Zhang Qiuxiang. Correlation between NT-proBNP, hs-CRP, left atrium diameter and chronic heart failure concurrent with atrial fibrillation [J]. Clinical Focus, 2021, 36(5): 412-415.
[13]	Geng Yanping, Wang Lili, Gu Jian, Qi Peng, Chen Shuxia. Validity and reliability analysis of Chinese version of AntiClot Treatment Scale [J]. Clinical Focus, 2020, 35(9): 788-791.
[14]	Yang Hua, Meng Limin, Xin Shuanli, Chang Chao, Zhao Xiufeng, Wang Min. Correlation between serum chemerin levels and degree of atrial fibrosis in patients with atrial fibrillation [J]. Clinical Focus, 2020, 35(3): 206-210.
[15]	Gao Xiuxina, Si Yueqiaoa, Ding Zhenjianga, Zhang Yinga, Liu Huilinga, Liu Jingyia, Han Chaoa, Sunwang Lexianaa. Correlation of platelet distribution width and red blood cell distribution width in peripheral blood with atrial fibrillation in patients with coronary artery disease [J]. Clinical Focus, 2020, 35(11): 984-987.

Efficacy and safety of rivaroxaban in elderly patients with nonvalvular atrial fibrillation complicated with cardiac insufficiency

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments